The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 119-125

  Schwarz, Kerstin ^a   Romanski, Annette ^a   Puccetti, Elena ^b   Wietbrauk, Sarah ^a   Vogel, Anja ^a   Keller, Maren ^a   Scott, Jeffrey W ^c   Serve, Hubert ^a   Bug, Gesine ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acute myeloid leukaemia; CD34+ progenitor cells; Deacetylase inhibitor; Notch signalling

Indexed keywords

CD34 ANTIGEN; DACINOSTAT; NOTCH RECEPTOR; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; GENE INDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; HEMATOPOIETIC STEM CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 78650176110     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.024     Document Type: Article

References (32)

1. Passegue E., Jamieson C.H., Ailles L.E., Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci USA 2003, 100(Suppl. 1):11842-11849.
2. Jordan C.T., Guzman M.L. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004, 23:7178-7187.
3. Kojika S., Griffin J.D. Notch receptors and hematopoiesis. Exp Hematol 2001, 29:1041-1052.
4. McElhinny A.S., Li J.L., Wu L. Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene 2008, 27:5138-5147.
5. Takeuchi J.K., Lickert H., Bisgrove B.W., Sun X., Yamamoto M., Chawengsaksophak K., et al. Baf60c is a nuclear Notch signaling component required for the establishment of left-right asymmetry. Proc Natl Acad Sci USA 2007, 104:846-851.
6. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003, 194:237-255.
7. Lin R., Nagy L., Inoue S., Shao W., Miller W., Evans R. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998, 391:811-814.
8. Wang J., Hoshino T., Redner R., Kajigaya S., Liu J. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin/HDAC1 complex. Proc Natl Acad Sci USA 1998, 95:10860-10865.
9. Ferrara F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., et al. Histone deacytylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001, 61:2-7.
10. Göttlicher M., Minucci S., Zhu J., Krämer O., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
11. Cimino G., Lo-Coco F., Fenu S., Travaglini L., Finolezzi E., Mancini M., et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006, 66:8903-8911.
12. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
13. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725.
14. Ottmann O., Spencer A., Prince H., Bhalla K., Fischer T., Liu A., et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood 2008, 112:a958.
15. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
16. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65:2537-2541.
17. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009, 106:3925-3929.
18. Rossmanith T., Schroder B., Bug G., Muller P., Klenner T., Knaus R., et al. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells. Stem Cells 2001, 19:313-320.
19. + cells from normal and myelodysplastic bone marrow. Blood 2002, 100:3553-3560.
20. Hao Z., Li X., Qiao T., Li S., Lv Y., Fan D. Downregulated expression of CIAPIN1 may contribute to gastric carcinogenesis by accelerating cell proliferation and promoting cell cycle progression. Cancer Biol Ther 2009, 8:1064-1070.
21. Bug G., Schwarz K., Schoch C., Kampfmann M., Henschler R., Hoelzer D., et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92:542-545.
22. Kao H.Y., Ordentlich P., Koyano-Nakagawa N., Tang Z., Downes M., Kintner C.R., et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998, 12:2269-2277.
23. Yamaguchi M., Tonou-Fujimori N., Komori A., Maeda R., Nojima Y., Li H., et al. Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development 2005, 132:3027-3043.
24. Hirata H., Yoshiura S., Ohtsuka T., Bessho Y., Harada T., Yoshikawa K., et al. Oscillatory expression of the bHLH factor Hes1 regulated by a negative feedback loop. Science 2002, 298:840-843.
25. Carlesso N., Aster J.C., Sklar J., Scadden D.T. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood 1999, 93:838-848.
26. Stockhausen M.T., Sjolund J., Manetopoulos C., Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 2005, 92:751-759.
27. Puccetti E., Zheng X., Brambilla D., Seshire A., Beissert T., Boehrer S., et al. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha. Cancer Res 2005, 65:6080-6088.
28. Yu X., Alder J.K., Chun J.H., Friedman A.D., Heimfeld S., Cheng L., et al. HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells 2006, 24:876-888.
29. + hematopoietic progenitor cells. Stem Cells 2007, 25:203-210.
30. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004, 101:1241-1246.
31. Viale A., De Franco F., Orleth A., Cambiaghi V., Giuliani V., Bossi D., et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457:51-56.
32. Salat D., Liefke R., Wiedenmann J., Borggrefe T., Oswald F. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes. Mol Cell Biol 2008, 28:3502-3512.